Diabetes and Hypertension Project ECHO* Clinic

*ECHO: Extension of Community Healthcare Outcomes

June 6, 2023

Before we begin:

- Rename your Zoom screen with your name and organization
- Claim CE:
- Go to **vcuhealth.org/echodmhtn** for instructions on creatin your account

The Diabetes and Hypertension ECHO is made possible by funding through CDC Cooperative Agreement NU58DP006620-InnoVAte.

Zoom Reminders



- You are all on mute. Please unmute to talk.
- If joining by telephone audio only, press *6 to mute and unmute.
- Use the chat function to speak with our team or ask questions.

Helpful Reminders

- Please feel free to eat your lunch or step away briefly if needed
- We are recording and can share sessions upon request
  - Each session's slides are available on www.vcuhealth.org/echodmhtn
- Please **do not share any protected health information** in your discussion or the chat box
- Project ECHO operates on the "All Teach, All Learn" model
  - Feel free to ask questions in the chat or unmute to ask questions at designated times
  - We're all here to learn from each other and value each person's input and expertise!

VCU Health Diabetes & Hypertension ECHO Clinics

VCU Hub Team	
Principal Investigator	Dave Dixon, PharmD
Clinical Experts	Niraj Kothari, MD Trang Le, MD
Program Coordinator	Sydney Weber

- One-hour ECHO clinics on 2nd Thursdays
- Every ECHO clinic includes a didactic presentation followed by case discussions
- Website: www.vcuhealth.org/echodmhtn
  - Directions for claiming CE :
  - You have up to six days after our session to claim CE by **texting 29387-28189** to **804-625-4041**

Disclosures

Trang Le, M.D., has no financial conflicts of interest to disclose.

Niraj Kothari, M.D., has no financial conflicts of interest to disclose.

There is no commercial or in-kind support for this activity.

Lighting Round - Diabetes!

Learning objectives

- Discuss indications for and benefits of pharmaceuticals for treatment of pre-diabetes
- Describe CGM use in type 2 diabetes(uncoupled from insulin pump) in elderly patients, along with sources of error in CGM

Prediabetes – prevention of diabetes

- Always, nutrition and physical activity: Diabetes Prevention Program!
- Over 3 years:
  - Lifestyle intervention (nutrition / exercise coaching goal 150 minutes physical activity per week and 7% weight loss): ↓ of developing diabetes by 58%, MORE effective in age >60 (↓risk by 71%)
  - Metformin 850mg BID: ↓ risk of developing diabetes by 31%, LESS effective in age 45+
- ADA Standards of care Recommendation 3.6:
  - *metformin therapy should be considered in adults at high risk of type 2 diabetes, per the Diabetes Prevention Program, especially in those aged 25-59 years with*
  - *BMI >= 35 kg/m2,*
  - *fasting plasma glucose >= 110,*
  - *higher A1c (>=6.0%)*
  - *prior gestational diabetes*

(Diabetes Care 2006;29:2102–2107)

True or False

- Metformin is approved by the U.S. FDA for a specific indication of Type 2 diabetes prevention

Which of the following have been evaluated for diabetes prevention?

A. Metformin
B. GLP-1 agonists
C. Testosterone
D. Insulin
E. Alpha-glucosidase inhibitors
F. Pioglitazone

Pioglitazone

- Cardiovascular outcome trials in people without diabetes also inform risk reduction potential in people without diabetes but at increased cardiometabolic risk
- IRIS (Insulin Resistance Intervention after Stroke): study of people with a recent (<6 months) stroke or transient ischemic attack, without diabetes but with insulin resistance (by HOMA-IR)
  - At 4.8 years, the risk of stroke or myocardial infarction, as well as the risk of diabetes, was *lower* within the pioglitazone group than with placebo,
  - risks of weight gain, edema, and fracture were *higher* in the pioglitazone treatment group

Inzucchi SE, Viscoli CM, Young LH, et al.; IRIS Trial Investigators. Diabetes Care 2016;39:1684–1692

Testosterone

- Randomized, double-blind, placebo-controlled, 2-year trial (Australia)
- Men aged 50-74 years, high BMI and a serum testosterone concentration 250-400 (lower end normal range + impaired glucose tolerance or newly diagnosed type 2 diabetes)
- Enrolled in a lifestyle program and then randomized to either placebo or testosterone treatment
- Testosterone treatment for 2 years reduced the proportion of participants with type 2 diabetes beyond the effects of a lifestyle program alone

Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45.

Weight loss

- In DPP, every 1kg of weight loss = 16% reduction in risk of progression, over 3.2 years (Diabetes Care 2006;29:2102–2107)

- Orlistat, phentermine toparimate, liraglutide, semaglutide, and tirzepatide have all been shown to decrease incidence of diabetes in those with prediabetes

Continuous Glucose Monitoring (CGM) in older adults

ADA Standards of Care 2023:

- Recommendation 13.5: For older adults with type 1 diabetes, continuous glucose monitoring is recommended to reduce hypoglycemia
- Recommendation 13.6: For older adults with Type 2 diabetes on multiple daily doses of insulin, CGM should be considered to improve glycemic outcomes and decrease glucose variability.
- Approved / covered by Medicare
- May significantly improve A1c, reduce glycemic variability, and risk of hypoglycemia

Wireless Innovations for Seniors with Diabetes Mellitus (WISDM) trial, n=203

- Median age 68, mean A1c 7.5%, 53% on insulin pumps
- Mean 56% of total time in target glucose range of 70-180 mg/dL and 37% of time above 180 mg/dL
- Over half of older T1D participants spent *at least an hour a day* with glucose levels <70 mg/dL
- Those with reduced hypoglycemia awareness spent over twice as much time than those without in a serious hypoglycemia range (glucose levels <54 mg/dL)

J Diabetes Sci Technol. 2021 May;15(3):582-592.

Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin (Diamond Trial)

- multicenter, randomized trial was conducted in the United States and Canada in which 116 individuals ≥60 years (mean 67 ± 5 years) with T1D (n = 34) or T2D (n = 82)
- Dexcom G4 or self-monitoring blood glucose
- HbA1c reduction from baseline to 24 weeks was greater in the CGM group than Control group (−0.9 ± 0.7% vs −0.5 ± 0.7%)
- CGM-measured time >250 mg/dL (P = .006) and glycemic variability (P = .02) were lower in the CGM group
- Low incidence of hypoglycemia in both groups so unable to detect a difference in hypoglycemia occurrences

CGM sources of inaccuracy

- *Why is it occasionally different from fingersticks and what "margin of error" is acceptable?*
- Unlike finger stick tests where the glucose levels are measured in capillary blood, CGM devices measure glucose in the interstitial fluid.
- Lag time of 5 to 20 minutes (mean 9 minutes) before the vascular and interstitial glucose levels equilibrate.
- Lag time can cause discrepancy, especially during rapid fluctuations.
- First day on a new sensor can have greater variability
- Pressure applied to sensor (example: sleeping on same side as sensor)

Dexcom

- The Dexcom G6 reading must be within:
- 20% of the meter value when the meter value is 80 mg/dL or higher
- 20 mg/dL of the meter value when the meter value is under 80 mg/dL

CGM interfering substances

Table 7.4—Continuous glucose monitoring devices interfering substances

Medication	Systems affected	Effect
Acetaminophen		
>4 g/day	Dexcom G6	Higher sensor readings than actual glucose
Any dose	Medtronic Guardian	Higher sensor readings than actual glucose
Alcohol	Medtronic Guardian	Sensor readings may be higher than actual glucose
Ascorbic acid (vitamin C), >500 mg/day	FreeStyle Libre	Higher sensor readings than actual glucose
Hydroxyurea	Dexcom G6, Medtronic Guardian	Higher sensor readings than actual glucose
Mannitol	Senseonics Eversense	Sensor bias within therapeutic concentration ranges
Tetracycline	Senseonics Eversense	Sensor bias within therapeutic concentration ranges

Ascorbic acid can be found in supplements including multivitamins. Some supplements, including cold remedies such as Airborne® and Emergen-C®, may contain high doses of 1000 mg of ascorbic acid

Lightning Round - June 8, 2023

When to refer patients to nephrology

Hypertensive urgency in the office

Learning objectives

- Discuss criteria for patient referral to nephrology
- Understand effects of HTN on various organs
- Distinguish HTN urgency from emergency
- Discuss management of HTN urgency

When should patients be referred to nephrology?

- Balance utilization with care needs
- Err on the side of referring
- Criteria:

- Acute kidney injury or abrupt sustained fall in GFR
- GFR <30 ml/min/1.73 m2 (GFR categories G4-G5)
- Persistent albuminuria (ACR > 300 mg/g)*
- Progression of CKD**
  - A certain drop in eGFR is defined as a drop in GFR category accompanied by a 25% or greater drop in eGFR from baseline.
  - Rapid progression is defined as a sustained decline in eGFR of more than 5 ml/min/1.73 m^2/year
- Urinary red cell casts, RBC more than 20 per HPF sustained and not readily explained
- CKD and hypertension refractory to treatment with 4 or more antihypertensive agents
- Persistent abnormalities of serum potassium
- Recurrent or extensive nephrolithiasis
- Hereditary kidney disease

GFR categories (ml/min/ 1.73 m^2) Description and range				Persistent albuminuria categories Description and range		
				A1	A2	A3
				Normal to mildly increased	Moderately increased	Severely increased
				<30 mg/g <3 mg/mmol	30–300 mg/g 3–30 mg/mmol	>300 mg/g >30 mg/mmol
	G1	Normal or high	≥90		Monitor	Refer*
	G2	Mildly decreased	60–89		Monitor	Refer*
	G3a	Mildly to moderately decreased	45–59	Monitor	Monitor	Refer
	G3b	Moderately to severely decreased	30–44	Monitor	Monitor	Refer
	G4	Severely decreased	15–29	Refer*	Refer*	Refer
	G5	Kidney failure	<15	Refer	Refer	Refer

https://doi.org/10.1038/kisup.2012.68

Case

- A 55 year old man presents to your primary care clinic for an annual physical. You note that his eGFR is 50mL/min/1.73m^2, compared to 90mL/min/1.73m^2 last year. How would you address this?
- A. Leave him alone
- B. Refer to nephrology
- C. Refer for dialysis catheter placement and to ER to start HD

What are the potential effects of HTN?



Hemorrhage, stroke, dementia

HTN



LVH, CHD, HF



Retinopathy



Peripheral vascular disease



Renal failure

Adapted from: JNC V. *Arch Intern Med.* 1993;153(2):154-183.

Hypertensive emergency

- Formerly known as malignant hypertension
- Patients may or may not have HTN history
- Progressive end-organ dysfunction
- Usually BP > 180/120mmHg
- Possible effects:
  - Acute LV failure
  - Pulmonary edema
  - Unstable angina or MI
  - Stroke
  - AKI
  - Neurologic symptoms/encephalopathy
    - Includes nausea/vomiting which may indicate increased ICP
  - Retinopathy (grade 3-4)
  - Chest pain/MI/aortic dissection
  - Eclampsia/preeclampsia



HTN effects on CNS

- Stroke
- Intracerebral and/or subarachnoid hemorrhage



HTN effects on eyes

- Retinopathy/retinal hemorrhage
- Vitreous hemorrhage
- Retinal detachment
- Neuropathy—can lead to extraocular muscle dysfunction or paralysis

Hypertensive retinopathy





Medium.com/@errantnephron

- AV nicking
- Papilledema
- Cotton wool spots
- Flame hemorrhage

Vitreous hemorrhage



https://retinaeyedoctor.com/wp-content/uploads/2018/03/Vitreous_Boat_Hemorrhage-768x687.png

Cardiovascular disease induced by HTN

- Left ventricular hypertrophy, dysfunction, failure
- Arrhythmias
- Arterial aneurysm/dissection/rupture
- CAD



HTN and kidney disease

- Glomerulosclerosis
- CKD -> ESKD
- Ischemic kidney disease (especially from renal artery stenosis/atherosclerosis)



Pulmonary edema

Normal CXR



http://www.chestx-ray.com/images/igallery/resized/1-100/9-18-500-500-100.jpg

Pulmonary edema



Hypertensive urgency

- No end-organ dysfunction
- Elevated BP (often > 180/120mmHg)

Hypertensive encephalopathy

- Emergency!
- Headache (usually nonlocalized) of moderate-severe intensity
- Altered mental status: somnolence, confusion, agitation, stupor
- Visual disturbances or hallucinations
- Loss of vision
- Seizures

Urgency vs. emergency

- Both will have severely elevated BP, however HTN urgency does not have signs or symptoms of end-organ damage.
  - Is it real?
    - Medication adherence
    - Stress
    - Pain
    - Home BP/white coat HTN
  - Usually treat “in office”—alter antihypertensive regimen (usually same day)
  - Increase medication regimen, but don’t go overboard
- HTN urgency does not necessarily require inpatient treatment or IV medications—HTN emergency does for more rapid BP lowering

Evaluation for end-organ damage

- History and physical exam!
  - Headaches, chest pain?
  - Papilledema?
  - Could see severe chest/back pain, weak pulses (carotid/brachial/femoral) and/or significant systolic BP variation in aortic dissection (depending on location)
- CXR
- EKG
- Urinalysis
- Serum electrolytes + creatinine
- Cardiac enzymes (i.e. troponin)
- CT of the brain, chest, and/or abdomen
- Ultrasound or echocardiogram

Autoregulation

- Lowering BP too quickly can lead to ischemia and target organ damage
- One example is cerebral autoregulation
  - Overly rapid BP lowering can lead to ischemic stroke



Lange 20.19

Case

- 47yo M presents to clinic for HTN followup
- Secondary HTN eval negative
- Meds: minoxidil 5mg TID, losartan 100mg daily, chlorthalidone 25mg daily, labetalol 400mg BID, clonidine patch 0.3mg daily, amlodipine 10mg daily
- BP 185/110, repeat measurement with similar BP
- Now what?
- A. Do nothing
- B. ER for management of HTN emergency
- C. Adjust meds but do not send to ER if he is asymptomatic

Questions?

Case Studies

- Anyone can submit cases: www.vcuhealth.org/echodmhtn
- Receive feedback from participants and content experts
- Earn **$150** for submitting and presenting

Provide Feedback

www.vcuhealth.org/echodmhtn

- Feedback
  - Overall feedback related to session content and flow?
  - Ideas for guest speakers?

Send us your feedback

vcuhealth.org/services/telehealth/for-providers/education/diabetes-and-hypertension-project-echo

For Providers

- Education
  - **Diabetes and Hypertension Project ECHO**
    - Our Team
    - Curriculum
    - Claiming CE Credit
    - Contact Us
  - VCU Nursing Home ECHO
  - VCU Health Palliative Care ECHO
  - Virginia Opioid Addiction ECHO
  - Virginia Sickle Cell Disease ECHO

Diabetes and Hypertension Project ECHO

Welcome to the Diabetes and Hypertension Extension for Community Health Outcomes or ECHO, a virtual network of multidisciplinary diabetes and hypertension experts. An ECHO model connects professionals with each other in real-time collaborative virtual sessions on Zoom. Participants present de-identified cases to one another, share resources, connect to each other, and grow in their expertise. This ECHO will address practice level issues and solutions related to managing complex patients with difficult to control diabetes and hypertension. Register now for an ECHO Session!

Network, Participate and Present

- Engage in a collaborative community with your peers.
- Listen, learn and discuss informational and case presentations in real-time.
- Take the opportunity to submit your de-identified case study for feedback from a team of specialists for diabetes and hypertension.
- Provide valuable feedback.
- Claim CE credit by texting in attendance.

Benefits

VCU Diabetes & Hypertension Project ECHO Clinics

2nd Thursdays — 12 p.m. to 1 p.m.

Mark Your Calendars — Next Session

July – Summer Break!

August 10, 2023: the Future of Kidney Care

September 14, 2023: the Future of Diabetes Care

Please register at www.vcuhealth.org/echodmhtn

Thank you for coming!

Reminder: Mute and Unmute to talk
Press *6 for phone audio
Use chat function for questions